General
Preferred name
ERITORAN
Synonyms
Eritoran sodium ()
B-1287 ()
E5564 ()
B1287 ()
Eritoran tetrasodium salt ()
E-5564 ()
ERITORAN TETRASODIUM ()
P&D ID
PD016228
CAS
185955-34-4
185954-98-7
Tags
drug candidate
Drug indication
Sepsis
insulin resistance
Leukemia
Drug Status
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Eritoran is a synthetic analogue of lipid A, the bacterial LPS component. It is referred to as a Toll-like receptor 4 (TLR4) antagonist, but rather than direct interaction, eritoran binds to MD-2 and prevents formation of the MD-2.TLR4 protein complex. Thus, eritoran appears to antagonise LPS-induced TLR4 activation.
Eritoran has been investigated as a therapeutic for the management of sepsis, but failed to show sufficient clinical effect . (GtoPdb)
Eritoran has been investigated as a therapeutic for the management of sepsis, but failed to show sufficient clinical effect . (GtoPdb)
DESCRIPTION
Eritoran is a TLR4 antagonist that is developed for the treatment of severe sepsis.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
5
BOC Sciences Bioactive Compounds
ChEMBL Drugs
DrugBank
DrugMAP
Guide to Pharmacology
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
47
Molecular Weight
1312.84
Hydrogen Bond Acceptors
15
Hydrogen Bond Donors
7
Rotatable Bonds
59
Ring Count
2
Aromatic Ring Count
0
cLogP
15.29
TPSA
300.61
Fraction CSP3
0.92
Chiral centers
11.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data

